Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Clinical trials sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., explained in plain language.
A Chinese pharmaceutical company, subsidiary of Fosun Pharma.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug FXS5626 put to the test: will it affect the Heart's rhythm? Results expected Sep 2026 (estimated)
- New pill could tame eye inflammation without needles Results expected Feb 2027 (estimated)
- New drug FXS887 enters first human tests for tough cancers Results expected Apr 2027 (estimated)
- New drug aims to reduce kidney damage in IgAN patients Results expected Sep 2027 (estimated)